# Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

**Authors:** Cornelius F. Waller, Julia Möbius, Adolfo Fuentes-Alburo

PMC · DOI: 10.1038/s41416-024-02769-6 · British Journal of Cancer · 2024-07-03

## Full-text entities

- **Chemicals:** trastuzumab (MESH:D000068878)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11300457/full.md

---
Source: https://tomesphere.com/paper/PMC11300457